Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)
BOLT Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
68.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
274.40%
BOLT Stock Analysis
BOLT
PE Ratio:
BOLT
PEG Ratio:
Not Available
BOLT
Forward EPS Growth (12 month):
0.00%
BOLT
PS Ratio:
1.5
BOLT
PSG Ratio:
BOLT
Forward Revenue Growth (12 month):
75.00%
BOLT Articles
No data was found